EGFR and Parkinson disease: Thiazolopyridine compounds are able to act as antitumor agents and potential therapeutic agents for Parkinson’s disease, through inhibition of the epidermal growth factor receptor (EGFR) and monoamine oxidase B, respectively [13,14].